Patients

ACTMonitor™

When tissue biopsies are not an option, our liquid biopsy solution ACTMonitor™ provides reliable information for the assessment on treatment response and the detection of potential drug resistance and cancer recurrence. Liquid biopsy is a non-invasive alternative to surgical biopsies through a simple blood draw, from which circulating tumor DNA (ctDNA) is analyzed. ctDNA consists of fragments of tumor DNA that have been released into the blood stream. Therefore, obtaining your ctDNA may help us understand your tumor even when tissue biopsies are not available.

ACTMonitor is suitable for patients with solid tumors

■Who are unable to undergo surgery

■Who have developed drug resistance

■With risk of cancer recurrence

■Who wish to monitor treatment response

Turnaround time:

14 calendar days after samples are received